KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to -$188000.0.

  • Rigel Pharmaceuticals' Change in Inventory rose 9437.8% to -$188000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 45335.77%. This contributed to the annual value of -$764000.0 for FY2024, which is 3481.23% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Change in Inventory stood at -$188000.0, which was up 9437.8% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Change in Inventory ranged from a high of $8.4 million in Q2 2025 and a low of -$3.3 million during Q3 2024
  • For the 5-year period, Rigel Pharmaceuticals' Change in Inventory averaged around $635894.7, with its median value being -$114000.0 (2021).
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 207851.24% in 2021, then tumbled by 109003.56% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' Change in Inventory (Quarter) stood at -$450000.0 in 2021, then surged by 540.67% to $2.0 million in 2022, then tumbled by 227.63% to -$2.5 million in 2023, then rose by 23.94% to -$1.9 million in 2024, then soared by 90.23% to -$188000.0 in 2025.
  • Its Change in Inventory stands at -$188000.0 for Q3 2025, versus $8.4 million for Q2 2025 and -$1.4 million for Q1 2025.